49 research outputs found
Insufficienza epatica acuta e suo trattamento con impianto intraperitoneale di epatociti nel ratto: studio delle modificazioni istologiche ed ultrastrutturali della cellula epatica
No full textMessa a punto di un metodo di misura del Sevofluorano urinario per il monitoraggio biologico delle esposizioni a basse concentrazioni
No full textVengono riportati i risultati preliminari delle associazioni tra i valori medi delle concentrazioni di sevoflurano (SF) e protossido d’azoto (PA) nei campioni urinari di 65 soggetti professionalmente esposti a basse concentrazioni ed i valori medi ambientali degli stessi anestetici rilevati in 12 sale operatorie nel 2004 in un ospedale lombardo.
I dati raccolti hanno dimostrato che la variabilità statistica spiegata dai rilievi biologici è superiore per il SF rispetto al PA. Il coefficiente di correlazione lineare è risultato di 0,47 per il PA e di 0,63 per il SF. L’ampiezza degli intervalli di confidenza sta ad indicare la considerevole variabilità dei dosaggi biologici. Una ulteriore standardizzazione delle variabili individuali e della tecnica analitica potrebbero migliorare ulteriormente le associazioni riscontrate
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
No full textBACKGROUND
Integrase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated with weight gain in several clinical trials and observational cohorts. However, whether weight gain associated with INSTIs and tenofovir alafenamide confers a higher risk of weight-related clinical events is unclear. We aimed to assess whether changes in BMI differentially increase hypertension or dyslipidaemia risk in people with HIV receiving INSTIs, tenofovir alafenamide, or both versus other contemporary regimens.
METHODS
This multicentre, prospective observational study analysed prospective data from RESPOND, an international consortium of HIV cohorts for which recruitment began in 2017 and is still ongoing from HIV clinics and hospitals in 37 European countries and Australia. Participants were eligible if they were aged 18 years or older, receiving INSTI-containing antiretroviral therapy (ART) regimens or a contemporary non-INSTI, did not have hypertension or dyslipidaemia at baseline, and had baseline and at least two follow-up BMI, lipid, and blood pressure measurements. We excluded participants without baseline CD4 or HIV RNA results and those receiving non-ART medications associated with weight changes, including antipsychotics and mood stabilisers, corticosteroids, insulin, and insulin secretagogues. They were followed up from baseline until the earliest hypertension or dyslipidaemia event, their last visit, or Dec 31, 2021, whichever was earlier. The primary outcomes were incidence of hypertension and dyslipidaemia, for which we used multivariable Poisson regression adjusted for time-updated BMI to determine unadjusted and adjusted incidence rate ratios (IRRs) of hypertension and dyslipidaemia in people receiving INSTIs, tenofovir alafenamide, or both, and tested for interaction between time-updated ART regimen and BMI.
FINDINGS
Of the 35 941 RESPOND participants, 9704 (7327 [75·5 %] male and 2377 [24·5%] female) were included in the hypertension analysis and 5231 (3796 [72·6%] male and 1435 [27·4%] female) were included in the dyslipidaemia analysis. In the univariable model, hypertension was more common in individuals receiving an INSTI with tenofovir alafenamide (IRR 1·70, 95% CI 1·54-1·88) or an INSTI without tenofovir alafenamide (1·41, 1·30-1·53) compared with those receiving neither INSTIs nor tenofovir alafenamide. Adjustment for time-updated BMI and confounders attenuated risk in participants receiving an INSTI with (IRR 1·48, 1·31-1·68) or without (1·25, 1·13-1·39) tenofovir alafenamide. Similarly, dyslipidaemia was more common in participants using tenofovir alafenamide with an INSTI (IRR 1·24, 1·10-1·40) and tenofovir alafenamide alone (1·22, 1·03-1·44) than in participants using neither INSTI nor tenofovir alafenamide. Adjustment for BMI and confounders attenuated the risk in participants receiving tenofovir alafenamide with an INSTI (adjusted IRR 1·21, 1·07-1·37), whereas the risk in those receiving tenofovir alafenamide alone became non-significant (1·15, 0·96-1·38). The associations between increasing BMI and risk of hypertension and dyslipidaemia did not differ between participants receiving different ART regimens (pinteraction=0·46 for hypertension; pinteraction=0·31 for dyslipidaemia).
INTERPRETATION
Although residual confounding cannot be entirely excluded, the use of INSTIs was associated with incident hypertension, and the use of tenofovir alafenamide was associated with dyslipidaemia, with the latter association partly mediated by weight gain. These results reiterate the need for hypertension and dyslipidaemia screening in people with HIV.
FUNDING
The CHU St Pierre Brussels HIV Cohort, The Austrian HIV Cohort Study, The Australian HIV Observational Database, The AIDS Therapy Evaluation in the Netherlands national observational HIV cohort, The Brighton HIV Cohort, The National Croatian HIV Cohort, The EuroSIDA cohort, The Frankfurt HIV Cohort Study, The Georgian National AIDS Health Information System, The Nice HIV Cohort, The ICONA Foundation, The Modena HIV Cohort, The PISCIS Cohort Study, The Swiss HIV Cohort Study, The Swedish InfCare HIV Cohort, The Royal Free HIV Cohort Study, The San Raffaele Scientific Institute, The University Hospital Bonn HIV Cohort, The University of Cologne HIV Cohort, Merck Life Sciences, ViiV Healthcare, and Gilead Sciences
SOLAR 12-month European results: Randomized switch trial of CAB plus RPV vs. oral BIC/FTC/TAF
No full textSOLAR 12-month European results: Randomized switch trial of CAB plus RPV vs. oral BIC/FTC/TAF
No full textPlasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers
No full textHighly efficient encapsulation and phase separation of apolar molecules by magnetic shell-by-shell-coated nanocarriers in water
No full textWe report on the development of a supramolecular nanocarrier concept that allows for the encapsulation and separation of small apolar molecules from water. The nanocarriers consist of shell-by-shell-coated nanoparticles such as TiO2 and ferromagnetic Fe3O4. The first ligand shell is provided by covalently bound hexadecyl phosphonic acid (PAC16) and the second shell by noncovalently assembled amphiphiles rendering the hybrid architecture soluble in water. Agitation of these constructs with water containing the hydrocarbons G1–G4, the fluorescent marker G5, the polychlorinated biphenyl PCB 77, or crude oil leads to a very efficient uptake (up to 411 ) of the apolar contaminant. In case of the hybrids containing a Fe3O4 core, straightforward phase separation by the action of an external magnet is provided. The load can easily be released by a final treatment with an organic solvent. © 2018 Wiley-VCH Verlag GmbH Co. KGaA, Weinhei
Nontuberculous extensive constrictive pericarditis calcarea impairing right ventricular filling in an HIV-infected patient: the key role of computed tomography imaging
No full textAsymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral therapy
No full textParonychia with pyogenic granuloma in a child treated with indinavir: the retinoid-mediated side effect theory revisited
No full text
